DOCSLIB.ORG

Preparations Ph

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Preparations Ph 1642 Corticosteroids Ointment; Colistin and Neomycin Sulfates and Hydrocortisone Preparations Ph. Bur. 8: (Methylprednisolone), A white or almost white, Acetate Otic Suspension; Hydrocortisone Acetate Cream; ·········································· crystalline powder. It shows polymorphism. Practically Hydrocortisone Acetate Injectable Suspension; Hydrocortisone Proprietary Preparations (details are given in Volume B) insoluble in water; sparingly soluble in alcohol; slightly Acetate Lotion; Hydrocortisone Acetate Ointment; Hydrocorti­ SingleRingredient Preparations. Arg.: Alrex; Lopred; Lotemax; soluble in acetone and in dichloromethane. Store at a sone Acetate Ophthalmic Ointment; Hydrocortisone Acetate Lotesoft; Talof; Austria: Lotemax; Braz. : Alrex; Loteprol; temperature of 2 degrees to 8 degrees. Protect from light. Ophthalmic Suspension; Hydrocortisone and Acetic Acid Otic Canad.: Alrex; Lotemax; Chile: Oftol; China: Lotemax Solution; Hydrocortisone Butyrate Cream; Hydrocortisone (il\1i3:iil'); USP 36: (Methylprednisolone), A white to practically white, Ger.: Lotemax; Gr.: Lotemax; Hong Kong: Alrex; Lotemax; Cream; Hydrocortisone Gel; Hydrocortisone Injectable Suspen­ odourless, crystalline powder. Practically insoluble in water; India: Loteflam; Lotepred; Irl. : Lotemax; Israel: Lotemax; Ital.: sion; Hydrocortisone Lotion; Hydrocortisone Oinnnent; Hydro­ soluble 1 in 100 of alcohol, and in l in 800 of chloroform Lotemax; Mex. : Loterex; Lotesoft; Pol. : Lotemax; Singapore: cortisone Rectal Suspension; Hydrocortisone Sodium Phosphate and of ether; slightly soluble in acetone; sparingly soluble in Lotemax; Thai.: Lotemax; Turk. : Lotemax; UK: Lotemax; USA: Injection; Hydrocortisone Sodium Succinate for Injection; Alrex; Lotemax; Venez. : Lotesoft. dioxan and in methyl alcohol. Store in airtight containers. Hydrocortisone Tablets; Hydrocortisone Valerate Cream; Hydro� Protect from light. cortisone Valerate Ointment; Neomycin and Polymyxin B Multi-ingredient Preparations. Arg. : Loternicin; Zylet; Braz.: Sulfates and Hydrocortisone Acetate Cream; Neomycin and Zylet; Israel: Zylet; Mex. : Zyleth; Singapore: Zylet; Thai.: Zylet; Polymyxin B Sulfates and Hydrocortisone Acetate Ophthalmic USA: Zylet. Suspension; Neomycin and Polymyxin B Sulfates and Hydro� cortisone Ophthalmic Suspension; Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Solution; Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Suspension; Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Acetate Ophthalmic Ointment; Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Ointment; Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Ophthalmic Ointment; Neomycin and Polymyxin B Sulfates, Bacitracin, and Hydrocortisone Acetate Ointment; Neomycin and Polymyxin B Sulfates, Bacitracin, and Hydrocortisone Acetate Ophthalmic Ointment; Neomycin and Polymyxin B Sulfates, Gramicidin, and Hydrocortisone Acetate Cream; Neomycin Sulfate and Hydrocortisone Acetate Cream; Neomycin Sulfate and Hydrocortisone Acetate Lotion; Neomycin Mazipredone is a corticosteroid used topically for Sulfate and Hydrocortisone Acetate Ointment; Neomycin Sulfate glucocorticoid activity (p. 1597. I). It is used as the Ph. Bur. 8: (Methylprednisolone Acetate). A white or and Hydrocortisone Acetate Ophthalmic Ointment; Neomycin hydrochloride with miconazole in the treatment of fungal almost white, crystalline powder. Practically insoluble in Sulfate and Hydrocortisone Acetate Ophthalmic Suspension; infections of the skin. water; sparingly soluble in alcohol and in acetone. Protect Neomycin Sulfate and Hydrocortisone Cream; Neomycin Sulfate When applied topically, particularly to large areas, when and Hydrocortisone Ointment; Neomycin Sulfate and Hydro� from light. the skin is broken, or under occlusive dressings, cortisone Otic Suspension; Oxytetracycline Hydrochloride and corticosteroids may be absorbed in sufficient amounts to USP 36: (Methylprednisolone Acetate). A white or Hydrocortisone Acetate Ophthalmic Suspension; Oxytetra· cause systemic effects (p. I6I5.3). The effects of topical practically white, odourless, crystalline powder. Soluble 1 cycline Hydrochloride and Hydrocortisone Ointment; Polymyxin in 1500 of water, I in 400 of alcohol, 1 in 250 of chloroform, B Sulfate and Hydrocortisone Otic Solution. corticosteroids on the skin are described on p. 1617.3. For recommendations concerning the correct use of corticoster­ and I in 1500 of ether; sparingly soluble in acetone and in oids on the skin, see p. 1599.2. methyl alcohol; soluble in dioxan. Store in airtight containers at a temperature of 25 degrees, excursions Preparations permitted between 15 degrees and 30 degrees. Protect from . ...................... ....... ..... .............. ........... .......... .......... light. ProprietaryPreparations (details are given in Volume B) Single-ingredient Preparations. Rus.: Depersolon (L(enep3onoH). Methylprednisolone Hydrogen Succinate Multi-ingredient Preparations. Hung. : Mycosolon; Pol.: Mycoso· (BANM, r/NNM) 1/9 Ion; Rus.: Mycosolon (MnK03onoH); Ukr.: Mycosolon (MHK030JlOH)t. Pharmacopoeias. In US for veterinary use only. M;'!predf'lisciria: Me!)rednlsohe; . rvu.-:p�e(fnis<)nUrn; 1o!l­ NSC527579; . USP 36: (Isoflupredone Acetate). Protect from light. Methylpredni;;one; Sdt-435s;.MenpeAHvl3oH, · 1 7a,21. :Dihydroxy- 16�'rnethyfpregna: l,4-dien<O: 3,11 ,20- Profile tridn<O. Isoflupredone acetate is a corticosteroid that has been used for its topical glucocorticoid activity (p. 1597.1) in allergic rhinitis. Isoflupredone is also employed in veterinary medicine. ProprietaryPreparations (details are given in Volume B) USP 36: (Meprednisone). Store in airtight containers at a temperature not exceeding 40 degrees. Protect from light. Israel: Multi-ingredient Preparations. Proaft. Ph. Bur. 8: (Methylprednisolone Hydrogen Succinate). A Profile white or almost white, hygroscopic powder. Practically insoluble in water; slightly soluble in dehydrated alcohol Meprednisone is a corticosteroid with mainly glucocorticoid Loteprednol Etabonate (BANM, USAN, r/NNM) ® and in acetone; dissolves in dilute solutions of alkali activity (p. 1597. 1), It has been given orally as either the hydroxides. Store in airtight containers. Protect from light. CD[)D,S604; Eta'bopcto de tot�pred�oi;HGP-1; Loteprednol, free alcohol or the acetate and by injection as the sodium USP 36: (Methylprednisolone Hen1isuccinate). A white or rti.!bon�te de; Lqtepredno( etcbqnato de; Loreprednol �thy! hemisuccinate. C:qrbonate; .· Lotepredno!i Eta bonas; · P:51i04; 11or.;r�peAHOJ1a nearly white, odourless or nearly odourless, hygroscopic solid. Very slightly soluble in water; freely soluble in alcohol; soluble in acetone. Store in airtight containers. ProprietaryPreparations (details are given in Volume B) Single-ingredient Preparations. Arg.: Cortipyren B; Deltisona B; Methylprednisolone Sodium Succinate Latisona Bt; Prednisonal; Prenolone; Rupesona B; Mex. : Lee­ (BANM, r/NNM) 1/9 tan. Methylprednisolone (BAN, r/NN) ® Meilprednizolon; ethylpred · :tyl nisolon; 6a�Me�h:flpred\1iso­ Profile lone; Me\�ylpresJnfsdon<O;f\1et!1y! prednis()lo�um; Metiipred.­ nisolona; MetHprednizolon; Metilp edrilzol6nas; .lv1etyfpred­ Loteprednol etabonate is a corticosteroid used for its � n is olon; MeJYyli pr.edr<rs olon1: NSC·l99S7; glucocorticoid activity (p. 1597.1) in the topical manage­ . ment of inflammatory and allergic disorders of the eye. It is MerMnnp��M3dno;;.· 1.1j3;l7o,2l-T rihyd roxy76CI·r!1ethylptegna� ,4-cllene:3,20- usually used as eye drops containing 0.2 or 0.5%. · 1 Prolonged application to the eye of preparations dione. containing corticosteroids has caused raised intra ·ocular CnH,o05cd74.5 pressure and reduced visual function. (AS 8.3:43·2. AT( -001M 01; HO.?AB04 USP 36: (Methylprednisolone Sodium Succinate). A white References. or nearly white, odourless, hygroscopic, amorphous solid. 1. Noble S, Goa KL. Loteprednol etabonate: clinical potential in the ATC VeT --.-- QD07A401;QD 10M02; OH02A B(M. Soluble I in 1.5 of water and 1 in I2 of alcohol; very slightly management of ocular inflammation. BioDrugs 1998; 10: 329-39. UNit '-'X4W1ZR7023. soluble in acetone; insoluble in chloroform and in ether. 2. Pavesio CE, DeCory HH. Treatment of ocular inflammatory conditions with loteprednol eta bonate. Br J Ophthalmo/ 2008; 92: 455-9. Pharmacopoeias. In Bur. (see p. vii), Jpn, and US. Store in airtight containers. Protect from light. All cross·references refer to entries in Volume A .
Load more

Recommended publications
  • Betamethasone
    Betamethasone Background Betamethasone is a potent, long-acting, synthetic glucocorticoid widely used in equine veterinary medicine as a steroidal anti-inflammatory.1 It is often administered intra-articularly for control of pain associated with inflammation and osteoarthritis.2 Betamethasone is a prescription medication and can only be dispensed from or upon the request of a http://en.wikipedia.org/wiki/Betamethasone#/media/File:Betamethasone veterinarian. It is commercially available .png in a variety of formulations including BetaVet™, BetaVet Soluspan Suspension® and Betasone Aqueous Suspension™.3 Betamethasone can be used intra-articularly, intramuscularly, by inhalation, and topically.4 When administered intra-articularly, it is often combined with other substances such as hyaluronan.5 Intra-articular and intramuscular dosages range widely based upon articular space, medication combination protocol, and practitioner preference. Betamethasone is a glucocorticoid receptor agonist which binds to various glucocorticoid receptors setting off a sequence of events affecting gene transcription and the synthesis of proteins. These mechanisms of action include: • Potential alteration of the G protein-coupled receptors to interfere with intracellular signal transduction pathways • Enhanced transcription in many genes, especially those involving suppression of inflammation. • Inhibition of gene transcription – including those that encode pro-inflammatory substances. The last two of these are considered genomic effects. This type of corticosteroid effect usually occurs within hours to days after administration. The genomic effects persist after the concentrations of the synthetic corticosteroid in plasma are no longer detectable, as evidenced by persistent suppression of the normal production of hydrocortisone following synthetic corticosteroid administration.6 When used judiciously, corticosteroids can be beneficial to the horse.
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • The Inhaled Steroid Ciclesonide Blocks SARS-Cov-2 RNA Replication by Targeting Viral
    bioRxiv preprint doi: https://doi.org/10.1101/2020.08.22.258459; this version posted August 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting viral 2 replication-transcription complex in culture cells 3 4 Shutoku Matsuyamaa#, Miyuki Kawasea, Naganori Naoa, Kazuya Shiratoa, Makoto Ujikeb, Wataru 5 Kamitanic, Masayuki Shimojimad, and Shuetsu Fukushid 6 7 aDepartment of Virology III, National Institute of Infectious Diseases, Tokyo, Japan 8 bFaculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Tokyo, Japan 9 cDepartment of Infectious Diseases and Host Defense, Gunma University Graduate School of 10 Medicine, Gunma, Japan 11 dDepartment of Virology I, National Institute of Infectious Diseases, Tokyo, Japan. 12 13 Running Head: Ciclesonide blocks SARS-CoV-2 replication 14 15 #Address correspondence to Shutoku Matsuyama, [email protected] 16 17 Word count: Abstract 149, Text 3,016 bioRxiv preprint doi: https://doi.org/10.1101/2020.08.22.258459; this version posted August 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 18 Abstract 19 We screened steroid compounds to obtain a drug expected to block host inflammatory responses and 20 MERS-CoV replication. Ciclesonide, an inhaled corticosteroid, suppressed replication of MERS-CoV 21 and other coronaviruses, including SARS-CoV-2, the cause of COVID-19, in cultured cells. The 22 effective concentration (EC90) of ciclesonide for SARS-CoV-2 in differentiated human bronchial 23 tracheal epithelial cells was 0.55 μM.
    [Show full text]
  • WO 2014/195872 Al 11 December 2014 (11.12.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/195872 Al 11 December 2014 (11.12.2014) P O P C T (51) International Patent Classification: (74) Agents: CHOTIA, Meenakshi et al; K&S Partners | Intel A 25/12 (2006.01) A61K 8/11 (2006.01) lectual Property Attorneys, 4121/B, 6th Cross, 19A Main, A 25/34 (2006.01) A61K 8/49 (2006.01) HAL II Stage (Extension), Bangalore 560038 (IN). A01N 37/06 (2006.01) A61Q 5/00 (2006.01) (81) Designated States (unless otherwise indicated, for every A O 43/12 (2006.01) A61K 31/44 (2006.01) kind of national protection available): AE, AG, AL, AM, AO 43/40 (2006.01) A61Q 19/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A01N 57/12 (2006.01) A61K 9/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, AOm 59/16 (2006.01) A61K 31/496 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/IB20 14/06 1925 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 3 June 2014 (03.06.2014) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Effects of Three Corticosteroids on Equine Articular Cocultures in Vitro
    Effects of Three Corticosteroids on Equine Articular Cocultures In Vitro Richard Angellas Trahan Thesis submitted to the faculty of the Virginia Polytechnic Institute and State University in partial fulfillment of the requirements for the degree of Master of Science In Biomedical and Veterinary Sciences Christopher R. Byron, Chair Linda A. Dahlgren R. Scott Pleasant April 27th, 2018 Blacksburg, VA Keywords: osteoarthritis, corticosteroid, osteochondral explant, isoflupredone acetate Effects of Three Corticosteroids on Equine Articular Cocultures In Vitro Richard Angellas Trahan Academic Abstract The objective was to compare the effects of three corticosteroids at various equimolar concentrations on equine articular explant co-cultures in an inflammatory environment. Synovial and osteochondral explant co-cultures from 6 equine cadavers were exposed to IL-1β (10 ng/mL) and various concentrations (10-4, 10-7, or 10-10 M) of MPA, TA, IPA. Concentrations of PGE2, MMP-13, LDH, and GAG in media were determined at 48 and 96 hours. Results indicated wells with low concentrations of MPA (10-7 and 10-10 M at 48 and 96 hours), TA (10-7 M at 48 hours and 10-7 and 10-10 M at 48 and 96 hours), and IPA -10 (10 M at 48 hours) had significantly less PGE2 than positive control samples. Groups -7 -10 with low concentrations (10 and 10 M) of MPA and TA had significantly less PGE2 than the highest concentration (10-4 M) at 48 hours. Significantly less MMP-13 was detected for all concentrations of MPA, TA, and IPA at 96 hours. The LDH assay results indicated cytotoxicity only for samples treated with IPA at 10-4 M at 48 and 96 hours.
    [Show full text]
  • General Agreement on Tariffs Andtrade
    RESTRICTED GENERAL AGREEMENT TAR/W/87/Rev.1 16 June 1994 ON TARIFFS AND TRADE Limited Distribution (94-1266) Committee on Tariff Concessions HARMONIZED COMMODITY DESCRIPTION AND CODING SYSTEM (Harmonized System) Classification of INN Substances Revision The following communication has been received from the Nomenclature and Classification Directorate of the Customs Co-operation Council in Brussels. On 25 May 1993, we sent you a list of the INN substances whose classification had been discussed and decided by the Harmonized System Committee. At the time, we informed you that the classification of two substances, clobenoside and meclofenoxate, would be decided later. Furthermore, for some of the chemicals given in that list, one of the contracting parties had entered a reservation and the Harmonized System Committee therefore reconsidered its earlier decision in those cases. I am therefore sending you herewith a revised complete list of the classification decisions of the INN substances. In this revised list, two substances have been added and the classifications of two have been revised as explained below: (a) Addition Classification of clobenoside, (subheading 2940.00) and meclofenoxate (subheading 2922.19). (b) Amendment Etafedrine and moxidentin have now been reclassified in subheadings 2939.40 and 2932.29 respectively. The list of INN substances reproduced hereafter is available only in English. TAR/W/87/Rev. 1 Page 2 Classification of INN Substances Agreed by the Harmonized System Committee in April 1993 Revision Description HS Code
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0099225A1 Freund Et Al
    US 20090099225A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0099225A1 Freund et al. (43) Pub. Date: Apr. 16, 2009 (54) METHOD FOR THE PRODUCTION OF Related U.S. Application Data PROPELLANT GAS-FREE AEROSOLS FROM (63) Continuation of application No. 1 1/506,128, filed on AQUEOUSMEDICAMENT PREPARATIONS Aug. 17, 2006, now Pat. No. 7,470,422, which is a continuation of application No. 10/417.766, filed on (75) Inventors: Bernhard Freund, Gau-Algesheim Apr. 17, 2003, now abandoned, which is a continuation (DE); Bernd Zierenberg, Bingen of application No. 09/331,023, filed on Sep. 15, 1999, am Rhein (DE) now abandoned. (30) Foreign Application Priority Data Correspondence Address: MICHAEL P. MORRIS Dec. 20, 1996 (DE) ............................... 19653969.2 BOEHRINGERINGELHEMI USA CORPORA Dec. 16, 1997 (EP) ......................... PCT/EP97/07062 TION Publication Classification 900 RIDGEBURY RD, P. O. BOX 368 RIDGEFIELD, CT 06877-0368 (US) (51) Int. Cl. A63L/46 (2006.01) (73) Assignee: Boehringer Ingelheim Pharma A63L/437 (2006.01) KG, Ingelheim (DE) (52) U.S. Cl. ......................................... 514/291; 514/299 (57) ABSTRACT (21) Appl. No.: 12/338,812 The present invention relates to pharmaceutical preparations in the form of aqueous solutions for the production of propel (22) Filed: Dec. 18, 2008 lant-free aerosols. US 2009/0099225A1 Apr. 16, 2009 METHOD FOR THE PRODUCTION OF 0008 All substances which are suitable for application by PROPELLANT GAS-FREE AEROSOLS FROM inhalation and which are soluble in the specified solvent can AQUEOUSMEDICAMENT PREPARATIONS be used as pharmaceuticals in the new preparations. Pharma ceuticals for the treatment of diseases of the respiratory pas RELATED APPLICATIONS sages are of especial interest.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0056488 A1 Teicher Et Al
    US 2010.0056488A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0056488 A1 Teicher et al. (43) Pub. Date: Mar. 4, 2010 (54) CORTICOSTEROD CONUGATES AND USES Publication Classification THEREOF (51) Int. Cl. (75) Inventors: Martin H. Teicher, Rye, NH (US); A6II 3/56 (2006.01) Susan L. Andersen-Navalta, C073/00 (2006.01) C07J 53/00 (2006.01) Medfield, MA (US) C07K I4/00 (2006.01) Correspondence Address: C07. 4I/00 (2006.01) CLARK & ELBNG LLP C08F 290/4 (2006.01) 101 FEDERAL STREET C07K 2/00 (2006.01) BOSTON, MA 02110 (US) COSB 37/00 (2006.01) C08G 69/48 (2006.01) (73) Assignee: The McLean Hospital A6IP37/06 (2006.01) Corporation, Belmont, MA (US) A6IP 29/00 (2006.01) (52) U.S. Cl. ......... 514/177: 552/611; 552/514; 530/395; (21) Appl. No.: 12/612,273 536/5: 525/50, 530/300; 536/55.1: 525/419 (22) Filed: Nov. 4, 2009 (57) ABSTRACT The invention features corticosteroids conjugated to either a Related U.S. Application Data charged group or a bulky group in a manner that resists in vivo Continuation of application No. 10/646,063, filed on cleavage, the resulting conjugate is a peripherally acting Ste (63) roid with reduced activity in the central nervous system. The Aug. 22, 2003, now abandoned. invention provides a method for treating a patient having an (60) Provisional application No. 60/405,688, filed on Aug. inflammatory disease by administering to the patient a corti 23, 2002. costeroid conjugate. US 2010/0056488 A1 Mar.
    [Show full text]
  • Different Strategies for Using Topical Corticosteroids in People with Eczema (Protocol)
    Cochrane Database of Systematic Reviews Different strategies for using topical corticosteroids in people with eczema (Protocol) Chalmers JR, Axon E, Harvey J, Santer M, Ridd MJ, Lawton S, Langan S, Roberts A, Ahmed A, Muller I, Long CM, Panda S, Chernyshov P, Carter B, Williams HC, Thomas KS Chalmers JR, Axon E, Harvey J, Santer M, Ridd MJ, Lawton S, Langan S, Roberts A, Ahmed A, Muller I, Long CM, Panda S, Chernyshov P, Carter B, Williams HC, Thomas KS. Different strategies for using topical corticosteroids in people with eczema. Cochrane Database of Systematic Reviews 2019, Issue 6. Art. No.: CD013356. DOI: 10.1002/14651858.CD013356. www.cochranelibrary.com Different strategies for using topical corticosteroids in people with eczema (Protocol) Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 BACKGROUND .................................... 1 OBJECTIVES ..................................... 4 METHODS ...................................... 4 ACKNOWLEDGEMENTS . 8 REFERENCES ..................................... 9 APPENDICES ..................................... 12 CONTRIBUTIONSOFAUTHORS . 13 DECLARATIONSOFINTEREST . 14 SOURCESOFSUPPORT . 15 Different strategies for using topical corticosteroids in people with eczema (Protocol) i Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Protocol] Different strategies for using topical corticosteroids in
    [Show full text]